Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir,ombitasvir,paritaprevir,ribavirin,ritonavir -

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;   - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.

United States - English - NLM (National Library of Medicine)

doh central pharmacy - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 200 mg - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. the following points should be considered when initiating therapy with kaletra: - the use of other active agents with kaletra is associated with a greater likelihood of treatment response [see clinical pharmacology (12.4) and clinical studies (14)] . - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra [see clinical pharmacology (12.4)] . the number of baseline primary protease inhibitor mutations affects the virologic response to kaletra [see clinical pharmacology (12.4)] . - once daily administration of kaletra is not recommended for therapy-experienced adult patients or any pediatric patients. ● kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme) to any of its ingredients, including ritonavir. ●  co-administration of kaletra is contraindicated with drugs t

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - ritonavir 100 mg - norvir tablets and oral solution are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. norvir oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with hiv-1 infection. - when co-administering norvir with other protease inhibitors, see the full prescribing information for that protease inhibitor including contraindication information. - norvir is contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (ten) or stevens-johnson syndrome) to ritonavir or any of its ingredients. - norvir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions. - norvir is contraindicated with drugs that are potent cyp3a inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possib

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 200 mg - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. the following points should be considered when initiating therapy with kaletra: - the use of other active agents with kaletra is associated with a greater likelihood of treatment response [see clinical pharmacology (12.4) and clinical studies (14)] . - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra [see clinical pharmacology (12.4)] . the number of baseline lopinavir resistance-associated substitutions affects the virologic response to kaletra [see clinical pharmacology (12.4)] . - once daily administration of kaletra is not recommended for any pediatric patients. - kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme) to any of its ingredients, including ritonavir. - co-administration of kaletra is contraindicated with drugs tha

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 200 mg - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. the following points should be considered when initiating therapy with kaletra: - the use of other active agents with kaletra is associated with a greater likelihood of treatment response [see clinical pharmacology (12.4) and clinical studies (14)] . - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra [see clinical pharmacology (12.4)] . the number of baseline lopinavir resistance-associated substitutions affects the virologic response to kaletra [see clinical pharmacology (12.4)] . - once daily administration of kaletra is not recommended for any pediatric patients. - kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme) to any of its ingredients, including ritonavir. - co-administration of kaletra is contraindicated with drugs th

United States - English - NLM (National Library of Medicine)

rebel distributors corp - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 200 mg - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. the following points should be considered when initiating therapy with kaletra: - the use of other active agents with kaletra is associated with a greater likelihood of treatment response [see clinical pharmacology (12.4) and clinical studies (14)] . - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra [see clinical pharmacology (12.4)] . the number of baseline lopinavir resistance-associated substitutions affects the virologic response to kaletra [see clinical pharmacology (12.4)] . - once daily administration of kaletra is not recommended for any pediatric patients. ● kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme) to any of its ingredients, including ritonavir. ●  co-administration of kaletra is contraindicated with drugs th

United States - English - NLM (National Library of Medicine)

hhs/program support center/supply service center - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 200 mg - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. the following points should be considered when initiating therapy with kaletra: - the use of other active agents with kaletra is associated with a greater likelihood of treatment response [see clinical pharmacology (12.4) and clinical studies (14)] . - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra [see clinical pharmacology (12.4)] . the number of baseline lopinavir resistance-associated substitutions affects the virologic response to kaletra [see clinical pharmacology (12.4)] . - once daily administration of kaletra is not recommended for any pediatric patients. - kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme) to any of its ingredients, including ritonavir. - co-administration of kaletra is contraindicated with drugs th

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. the following points should be considered when initiating therapy with kaletra: - the use of other active agents with kaletra is associated with a greater likelihood of treatment response [see clinical pharmacology (12.4) and clinical studies (14)] . - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra [see clinical pharmacology (12.4)] . the number of baseline lopinavir resistance-associated substitutions affects the virologic response to kaletra [see clinical pharmacology (12.4)] . - once daily administration of kaletra is not recommended for any pediatric patients. - kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme) to any of its ingredients, including ritonavir. - co-administration of kaletra is contraindicated with drugs tha

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - ritonavir 100 mg - norvir is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. when co-administering norvir with other protease inhibitors, see the full prescribing information for that protease inhibitor including contraindication information. norvir is contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (ten) or stevens-johnson syndrome) to ritonavir or any of its ingredients. norvir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions. norvir is contraindicated with drugs that are potent cyp3a inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance. table 2. drugs that are contraindicated with norvir drug class drugs within class that are contraindicated with norvir**